Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …

Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly
emerging a promising new treatment for haematological and non-haematological …

The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Investigators developed chimeric antigen receptors (CAR s) for expression on T cells more
than 25 years ago. When the CAR is derived from an antibody, the resultant cell should …

Immunotherapy with T cells genetically modified to express chimeric Ag receptors (CARs)
that target tumor-associated molecules have impressive efficacy in hematological …

Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells
against haematological malignancy, solid tumors impose a far greater challenge to success …

Simple Summary Certain immune cells, namely T cells, of cancer patients can be genetically
manipulated to express so-called chimeric antigen receptors (CARs), which enables these …

Chimeric antigen receptor (CAR)-T cells have emerged as a promising treatment modality
for various hematologic and solid malignancies over the past decade. Animal models …